Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vitae Pharmace Cm ST (VTAE)

Vitae Pharmace Cm ST (VTAE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vitae Pharmace Cm ST 502 WEST OFFICE CENTER DRIVE FORT WASHINGTON PA 19034

www.vitaepharma.com P: 215-461-2000

Description:

Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company. It is focused on discovering and developing small molecule drugs for diseases. The Company addresses multiple disease areas including diabetes, Alzheimer's disease, autoimmune disorders, atopic dermatitis, and acute coronary syndrome. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for Alzheimer's disease. Vitae Pharmaceuticals, Inc. is headquartered in Fort Washington, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 605,390
Shares Outstanding, K 28,840
Annual Sales, $ 580 K
Annual Net Income, $ -43,980 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,410 K
60-Month Beta 0.51
% of Insider Shareholders 14.80%
% of Institutional Shareholders 72.95%

Growth:

1-Year Return 81.03%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.36 on 08/03/16
Latest Earnings Date 11/03/16
Earnings Per Share ttm -1.93
EPS Growth vs. Prev Qtr 15.91%
EPS Growth vs. Prev Year 17.78%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

VTAE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -65.51%
Return-on-Assets % -59.63%
Profit Margin % -7,582.76%
Debt/Equity 0.00
Price/Sales 1,043.78
Price/Cash Flow N/A
Price/Book 8.29
Book Value/Share 2.53
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar